Focus on COVID-19 Prevention Intensifies for Patients With Cancer as FDA Removes Emergency Use Authorization for Evushield

Kathleen Wiley, RN, MSN, AOCNS®


On January 26, 2023 the U.S. Food and Drug Administration (FDA) removed its emergency use authorization (EUA) of tixagevimab/cilgavimab (Evushield) for the prevention of SARS-CoV-2 infection after exposure to the virus. FDA said it made the decision because the agent is not effective in preventing infections from the current variants that are responsible for 90% of today’s infections and because the risks of the drug’s side effects do not outweigh the benefits.

View Article @

ONS Voice Articles

Dive into a rich source of oncology nursing expertise with ONS articles.

View All Voice Articles